MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why CTXR Stock surged +4.07% Today — RQD Quant Desk Flash
$0.56 +4.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.56
Citius Pharmaceuticals Inc. (CTXR) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $15.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.56 (+0.54%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTXR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY CTXR SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (31% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (27% of score)
FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 53.6 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.50-8% Next Q
41
Q2 (-2Q)Grade D$0.46-13% Next Q
44
Q3 (-1Q)Grade D$0.40+40% Next Q
46
CurrentGrade D$0.56-5.4% Hist 90D α
49
Trajectory: D (41) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CTXR Turnaround Squeeze
While CTXR currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.54) and Max Pain ($0.59) forces dealer call-delta covering toward $1.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTXR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CTXR Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CTXR Stock surged +4.07% Today — RQD Quant Desk Flash
Citius Pharmaceuticals Inc. (CTXR) surged +4.07% to $0.56, trading at 15% of its 52-week range ($0.37 – $1.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($0.37 – $1.6) with RSI-14 at 53.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.56 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CTXR Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTXR)
- ✓Walkthrough of CTXR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CTXR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.00%📐 HORIZONTAL RANGE
2026-10-30O $0.56H $0.56L $0.52C $0.56VOL 99.6K
RES: $0.92SUP: $0.35SMA50: $0.54SMA200: $0.66
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CTXR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CTXR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CTXR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTXR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTXR)
Health Care Rank #368 of 1016
⚔️ NCEL vs CTXR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CTXR vs. NCEL, JAGX, OPTH, RADX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Citius Pharmaceuticals Inc. (CTXR) ranks #368 by composite RQD confidence (49/100, grade D) and #858 by equity capitalization ($15.5M). Within this direct 5-issuer industry benchmark cohort, CTXR leads on earnings valuation at N/A trailing P/E, while CTXR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with CTXR at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CTXR
ACTIVE
Citius Pharmaceuticals Inc. | D | 49/100 | — | — | -35.0% | +4.07% | $15.5M | Benchmark Subject |
| NCEL NewcelX Ltd. | D- | 39/100 | — | — | -35.0% | -0.30% | $15.5M | /ncel-vs-ctxr → |
| JAGX Jaguar Health Inc. | E | 31/100 | — | 67.2% | -35.0% | -2.86% | $15.9M | /jagx-vs-ctxr → |
| OPTH Optimi Health Corp. | D | 49/100 | — | — | — | -6.81% | $14.9M | /opth-vs-ctxr → |
| RADX Radiopharm Theranostics Limited | C- | 61/100 | — | — | — | +17.52% | $16.1M | /radx-vs-ctxr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001506251In its most recent audited fiscal period (FY2025, filed 2025-09-30), Citius Pharmaceuticals Inc. (CTXR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $0, operating cash flow of -$26.6M, and free cash flow of -$26.6M (+5.8% YoY). On the balance sheet, CTXR closed FY2025 with $140.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $0 | $0 | -$26.6M | -$26.6M | $140.4M | — |
| FY2024 (FY) | 2024-09-30 | $0 | $0 | -$28.2M | -$28.2M | $120.7M | — |
| FY2023 (FY) | 2023-09-30 | $0 | -$32.5M | -$29.1M | -$29.1M | — | — |
3. CTXR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CTXR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.56 (+4.07% 1D, market cap $15.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CTXR ranks #368 in composite RQD confidence.
How does CTXR compare to NCEL and JAGX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTXR carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NCEL (NewcelX Ltd.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $15.5M) and JAGX (Jaguar Health Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.9M). Among the 5-stock peer group, CTXR leads on earnings multiple (N/A) while CTXR leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CTXR?
Per CTXR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001506251), Citius Pharmaceuticals Inc. generated $0 in revenue, $0 in net income, and -$26.6M in free cash flow against $140.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CTXR trading relative to its 50-day, 200-day, and 52-week technical levels?
CTXR last traded at $0.56 (+4.07% on volume of 403,040 shares), positioning the stock +3.70% above its 50-day simple moving average ($0.54) and -15.15% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.37 to $1.60, CTXR sits at the 15.4% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.63).
CTXR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CTXR stock moving today?
Why CTXR Stock surged +4.07% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.